Alliance Pharma
Alliance Pharma plc, headquartered in Great Britain, is a prominent player in the pharmaceutical industry, specialising in the development and commercialisation of innovative healthcare products. Founded in 1998, the company has established a strong presence in various operational regions, including Europe and Asia, focusing on prescription medicines and over-the-counter products. With a diverse portfolio that includes unique formulations and niche therapeutic areas, Alliance Pharma is recognised for its commitment to quality and patient care. The company has achieved significant milestones, including strategic acquisitions that have bolstered its market position. Notably, Alliance Pharma has garnered accolades for its effective product range, which addresses unmet medical needs and enhances patient outcomes.
DitchCarbon Score
How does Alliance Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alliance Pharma's score of 42 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alliance Pharma's reported carbon emissions
In 2023, Alliance Pharma reported total carbon emissions of approximately 101,050 kg CO2e in Great Britain. This figure includes 45,580 kg CO2e from Scope 2 emissions, primarily from purchased electricity, and 55,470 kg CO2e from Scope 3 emissions, specifically from upstream transportation and distribution. Notably, there is no reported data for Scope 1 emissions for this year. Globally, Alliance Pharma's total emissions reached about 50,138,000 kg CO2e, with Scope 1 emissions at 2,000 kg CO2e, Scope 2 emissions at 59,000 kg CO2e (location-based), and a significant 50,125,000 kg CO2e from Scope 3 emissions. The latter includes substantial contributions from purchased goods and services, upstream transportation, and business travel. In 2022, the company reported total emissions of approximately 91,420 kg CO2e in Great Britain, with Scope 1 emissions at 1,570 kg CO2e and Scope 2 emissions from purchased electricity at 44,460 kg CO2e. The Scope 3 emissions for that year were primarily driven by upstream transportation and distribution. Despite these emissions figures, Alliance Pharma has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company’s emissions data is not cascaded from a parent organization, and all reported figures are directly attributed to Alliance Pharma plc. Overall, while Alliance Pharma has made strides in measuring its carbon footprint, further commitments and reduction strategies may be necessary to align with industry standards and climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 7,000 | 00,000 | 0,000 | 0,000 | - |
| Scope 2 | 107,000 | 00,000 | 00,000 | 00,000 | 0,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alliance Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
